Investigators found that the co-mutated KRAS/SMARCA4 NSCLC patients had worse survival vs. KRAS-mutated/SMARCA4 wild-type patients (hazard ratio [HR] = 1.882, p < 0.00001) [14]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.